2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2520

Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World
Abstract Number: 813

Incidence of Herpes Zoster in Patients with Polymyalgia Rheumatica: A Population-Based Cohort Study
Abstract Number: 142

Incidence of Hip Fracture in Rheumatoid Arthritis: British Columbia, Canada
Abstract Number: 2391

Incidence of Infections in Early Arthritis
Abstract Number: 545

Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry
Abstract Number: 1364

Incidence of Rheumatoid Arthritis in a Cohort of First Degree Relatives from the Studies of the Etiology of Rheumatoid Arthritis
Abstract Number: 16L

Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Abstract Number: 1429

Incidence Rates of Adverse Events with Death As an Outcome during Abatacept Treatment in RA: Results from an Integrated Data Analysis from 16 Clinical Trials
Abstract Number: 1769

Incidence, Predictors, and Outcome of Diffuse Alveolar Hemorrhage in Patients with MPO-ANCA Positive Microscopic Polyangiitis: A Multi-Center Retrospective Cohort Study
Abstract Number: 2945

Incident Hand OA Is Strongly Associated with Reduced Peripheral Blood Leukocyte Telomere Length
Abstract Number: 102

Incorporating Temporal Artery Ultrasound in a UK District General Hospital with No Prior Colour Doppler Sonography Service: An Encouraging Preliminary Analysis
Abstract Number: 1583

Increase in Arginase Activity and Related Arginine Metabolites in Patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA): Potential Mechanisms for Endothelial Dysfunction
Abstract Number: 993

Increase in Prevalence of Psoriasis Arthritis over Time: Analysis of Claims Data from 65 Million People in Germany from 2009 to 2012
Abstract Number: 1611

Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Abstract Number: 2406

Increased Cartilage Damage in Metacarpophalangeal Joints of ACPA Positive Rheumatoid Arthritis (RA) Patients Using T2 Mapping in 3 Tesla Magnetresonance Imaging (MRI)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].